Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.08
12.29
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Inventory
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
|
Inventory
ÂĄ6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
20%
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Inventory
ÂĄ575.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Inventory
ÂĄ4.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
||
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Inventory
ÂĄ2.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
||
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Inventory
ÂĄ6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
2%
|
||
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Inventory
ÂĄ140.9m
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands as a prominent player in the global pharmaceutical landscape, carving its niche with a remarkable story of specialization and expansion. Founded in 1998, the company first made its mark as a leading producer of heparin sodium, a critical anticoagulant used worldwide to prevent and treat blood clots. Operating from Shenzhen, China, Hepalink has meticulously built an integrated production chain that spans from the procurement of raw materials to the sale of finished pharmaceutical products. The company sources raw heparin from porcine intestines, which it then processes into pharmaceutical-grade heparin and low molecular weight heparins (LMWHs), leveraging its proprietary purification and synthesis technologies. This robust vertical integration not only ensures quality control but also bolsters its competitive positioning in global markets, where it serves hospitals, pharmaceutical companies, and research institutions. Beyond its heparin-centric foundation, Hepalink has strategically expanded its portfolio through a series of calculated ventures and acquisitions aimed at broadening its business model and revenue streams. Over the years, it has diversified into contract development and manufacturing services (CDMO), biotechnology innovations, and the production of other complementary pharmaceutical products. Its acquisition strategies, such as the purchase of U.S.-based Cytovance Biologics, have been pivotal in gaining an international footprint and enriching its expertise in biologics. By investing in research and development, Hepalink continues to explore biologically derived treatments, aiming to lead in therapeutic areas like oncology and cardiology. This diversification effort not only mitigates the risks inherent in relying heavily on a single product line but also positions Hepalink as an agile and innovative player, ready to navigate the ever-evolving pharmaceutical industry landscape.
See Also
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Inventory?
Inventory
6B
CNY
Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Inventory amounts to 6B CNY.
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Inventory growth rate?
Inventory CAGR 10Y
20%
Over the last year, the Inventory growth was -23%. The average annual Inventory growth rates for Shenzhen Hepalink Pharmaceutical Group Co Ltd have been 13% over the past three years , 24% over the past five years , and 20% over the past ten years .